Massive Bio Reticulum Nexus

Massive Bio is an AI-powered oncology company that connects cancer patients with clinical trials, with a January 2026 press release datelined San Francisco. The website does not state a founding year. It cites 200,000+ onboarded patients and 19,000+ oncology and hematology trials.

Reticulum Nexus is an AI-first operating system that coordinates more than 100 specialized agents across the enrollment lifecycle: medical record collection, eligibility assessment, trial strategy, site coordination and patient navigation. Other products include the Synergy AI Cancer Trial Finder app, Patient Connect and Trial Relay for physicians.

• Reticulum Nexus: orchestrates 100+ AI agents across the enrollment lifecycle.
• Eligibility assessment: agents assess records against trial criteria.
• Synergy AI Trial Finder: mobile app for patients to find cancer trials.
• Trial Relay: tool for physicians to find, screen and refer patients.
• Patient Connect: tool for patients and caregivers to navigate the trial journey.
• Patient navigation: last-mile concierge services.

CROs coordinating oncology studies across Southeast Asia could use agent workflows for eligibility checks. Hospitals could use Trial Relay to refer patients to open international trials.

Automates record collection and eligibility assessment through agent workflows. Coordinates patients, sites and sponsors in one system. Offers patient navigation with concierge support. The site lists HIPAA, GDPR, SOC and DiMe Seal 2026 compliance and 12 interface languages.

Sponsors are testing multi-agent AI to coordinate enrollment end to end, beyond simple matching. Cancer patients in Vietnam often seek trials abroad, so patient-facing finders and navigation may find demand.

Co-founders Selin Kurnaz (CEO), Arturo Loaiza-Bonilla and Cagatay Culcuoglu. States operations in 17 countries and a team of over 100. Founding member of the CancerX partnership.